Bayer and Onyx announce new data on dual mechanism of action of BAY 43-9006

WEST HAVEN, CT and RICHMOND, CA November 20, 2003 Bayer Pharmaceuticals Corporation (NYSE: BAY) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced today new preclinical data on the proposed anti-tumor activity of the investigational drug BAY 43-9006, indicating that the novel signal transduction inhibitor exhibits a dual mechanism of action targeting both cell proliferation and angiogenesis (the formation of new blood vessels to support cancer cell growth). The data were presented at the American Association for Cancer Research-National Cancer Institute-European Organization for Research and Treatment of Cancer (AACR-NCI-EORTC) meeting in Boston, USA.

BAY 43-9006 is the first compound that is known to target both Raf kinase and VEGFR2 to inhibit two essential mechanisms involved in tumor growth. Raf kinase is a key enzyme in an important growth signaling pathway associated with the proliferation of tumor cells. VEGFR2 is a main receptor of the vascular endothelial growth factor (VEGF), which plays a key role in angiogenesis.

Additionally, updated Phase II clinical data was presented at the meeting, evaluating BAY 43-9006 as a potential treatment of advanced renal cell carcinoma (RCC, or kidney cancer).

"BAY 43-9006 exhibits dual activity in important mechanisms that inhibit cancer progression. These findings suggest that BAY 43-9006 may have a potential role in the treatment of a range of cancers," said Susan Kelley, M.D., vice president, Oncology, Bayer Pharmaceuticals Corporation. "Besides kidney cancer, Bayer and Onyx are also evaluating this novel compound as a treatment for melanoma, liver, pancreatic and other cancers."

Interim Phase II Study Results
Bayer and Onyx also released an updated data analysis of Phase II clinical results that were first presented in October 2003. The updated data analysis included 50 participants with advanced and progressive RCC who were evaluable after 12 weeks of treatment. Of

Contact: Kelly Thornicroft
GCI Group

Page: 1 2 3 4

Related medicine news :

1. Yale cardiovascular researcher named Bayer Fellow 2004-05
2. Novartis announces collaboration with Bayer for EMSELEX
3. The Gerontological Society of America announces Hartford Fellowship recipients
4. TB Alliance announces new drug discovery program with GlaxoSmithKline
5. New ways to design safer & more effective topical (transdermal) drug delivery announced in the PNAS
6. IADR & GSK announce 2005 Innovation in Oral Care Awards
7. Innovation prize finalists announced in Science of Better
8. ASGE announces grant recipients in annual research awards program
9. The American Academy of Nurse Practitioners and Blackwell Publishing announce partnership
10. ESMO and Imedex announce partnership for the World Congress on Gastrointestinal Cancer
11. Voluntary health organizations, publishers announce major information initiative

Post Your Comments:

(Date:9/3/2020)... , ... September 03, 2020 , ... ... Show 2021 will be held Wednesday, April 7, to Saturday, April 10, 2021, ... , Medical Spa Show is a national trade show for non-invasive medical aesthetic ...
(Date:9/1/2020)... ... September 01, 2020 , ... ... $3 million convertible note financing, which will be used to accelerate the commercialization ... from this financing, the company will continue to expand its customer base of ...
(Date:8/31/2020)... YORK (PRWEB) , ... August 31, 2020 , ... ... nation’s largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving ... patient services – today announced the 10th Anniversary of Blood Cancer Awareness Month ...
(Date:8/31/2020)... ... August 31, 2020 , ... Colorado State University Global (CSU ... affordable online education – is proud to announce its new master’s degree in ... its kind in the nation, the 60-credit hour program is designed to provide ...
(Date:8/31/2020)... ... August 31, 2020 , ... Dr. Chang has over 20 ... and other developmental disabilities, as well as supporting staff in caring for patients ... school consultation, and staff development. She joined the company in 2015 as Chief ...
Breaking Medicine News(10 mins):
(Date:8/31/2020)... ... August 31, 2020 , ... Continuing ... - a broad-spectrum sanitization, disinfection and deodorization provider - is proud to announce ... and disinfecting services for businesses and residents throughout the area. , Germinator provides ...
(Date:8/27/2020)... ... August 27, 2020 , ... ... today announced the successful completion of their 2020 System and Organizational Controls (SOC) ... HITRUST® interim assessment and MARS-E compliance assessment. These achievements reflect their long-standing commitment ...
(Date:8/27/2020)... ... August 27, 2020 , ... Bridge To A Cure Foundation announces the appointment ... and pediatric neuro-oncologist who serves on the Board of Directors at The Preston Robert ... Medical School. , Internationally recognized, Dr. Friedman is a widely published author of more ...
Breaking Medicine Technology:
Cached News: